Proprietary subcutaneous delivery platform. Lead program is exenatide, a transformational once- or twice-yearly treatment for type 2 diabetes. Clinical stage.
Boston, MA
Intarcia Therapeutics
Recent Posts
Archives
- March 2026
- December 2025
- November 2025
- June 2025
- April 2025
- February 2025
- December 2024
- October 2024
- September 2024
- August 2024
- June 2024
- May 2024
- April 2024
- March 2024
- February 2024
- December 2023
- November 2023
- October 2023
- August 2023
- July 2023
- June 2023
- May 2023
- April 2023
- January 2023
- November 2022
- October 2022
- August 2022
- June 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- February 2020
- January 2020
- December 2019
- October 2019
- September 2019
- August 2019
- June 2019
- May 2019
- March 2019
- February 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- December 2014
Recent Comments